Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.37 |
| ▸ | RRM1 | P23921 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1968165 | 0.89 | ESR1 (0.50) | ALDH1A1LMNAHSD17B10ESR1ESR2 | |
| SCHEMBL705659 | 0.84 | SMN1; SMN2 (0.45) | ALDH1A1LMNAHSD17B10SMN1; SMN2MEN1 | |
| SCHEMBL1969740 | 0.83 | ESR1 (0.50) | ALDH1A1LMNAESR1ESR2SMN1; SMN2 | |
| SCHEMBL1967355 | 0.82 | ALDH1A1 (0.47) | ALDH1A1ESR1ESR2SMN1; SMN2MEN1 | |
| SCHEMBL1969471 | 0.79 | ESR1 (0.47) | ESR1ESR2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1972977 | 0.78 | ESR1 (0.46) | ALDH1A1ESR1ESR2SMN1; SMN2MEN1 | |
| SCHEMBL1967839 | 0.77 | SMN1; SMN2 (0.45) | ALDH1A1ESR1ESR2SMN1; SMN2MEN1 | |
| SCHEMBL1967257 | 0.76 | ESR1 (0.49) | ESR1ESR2MEN1KMT2AMIF | |
| SCHEMBL1968294 | 0.76 | ESR1 (0.49) | ESR1ESR2MEN1KMT2AMIF | |
| SCHEMBL1968316 | 0.75 | ESR1 (0.48) | ESR1ESR2SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168667-B2 | Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such | GALAPAGOS NV (BE) | 2012-05-01 | — | — | US | disclosed |
| EP-2026799-B1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | GALAPAGOS SAS (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-20100210699-A1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | DART THERAPUTICS, LLC. | 2010-08-19 | — | — | US | disclosed |
| US-20100063120-A1 | Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such | SASU, GALAPAGOS (FR) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210699-A1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | NR5A1, AR, HSD17B7 | ALDH1A1 300/4885LMNA 4085/4885HSD17B10 104/4885 |
| US-20100063120-A1 | Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such | NR5A1, AR, HSD17B7 | ALDH1A1 290/4885LMNA 4071/4885HSD17B10 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.